eligibility_summary
Eligible: adults ≥18 with relapsed/refractory CD20+ B‑cell NHL after ≥1 anti‑CD20 regimen, with no effective options, ECOG 0–1, life exp ≥3 mo, measurable disease, adequate marrow/liver/kidney function. Exclude: CLL/Burkitt/lymphoplasmacytic, CNS disease, active infection, recent anti‑cancer therapy or major surgery (<28 d), autoimmune disease, severe mAb reactions, uncontrolled illness, other recent cancers, PML, bleeding disorders, HIV/HBV/HCV, pregnancy/lactation, FCBP contraception 12 mo.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05806099 tests MBS303, an IV T‑cell–engaging bispecific antibody (immunotherapy) for relapsed/refractory CD20+ B‑cell NHL. Mechanism: MBS303 binds CD20 on malignant B cells and CD3 on T cells, forming an immune synapse that activates TCR/CD3 signaling, triggers T‑cell cytotoxicity (perforin/granzyme) and cytokine release, and depletes B cells. Optional pre‑treatment with MIL62 (an anti‑CD20 monoclonal antibody) is used to debulk CD20+ cells and mitigate cytokine‑release risk. Targets: CD20+ B cells and T cells via CD3, pathways engaged include TCR/CD3 activation and downstream cytotoxic/cytokine pathways leading to B‑cell killing.